Fufeng Pharmaceutical (601089.SH) announced that recently, the company received the approval and issuance of the National Medical Products Administration...
According to the financial news app, Fufeng Pharmaceutical (601089.SH) issued an announcement recently, that the company has received the "Drug Clinical Trial Approval Notice" for the hydrochloride maobu yunxiang alkali eye drops approved and issued by the National Medical Products Administration. The company applied for the clinical trial of hydrochloride maobu yunxiang alkali eye drops, indicated for the treatment of presbyopia in adults, administered via ocular route, classified as a chemical drug Class 3. As of now, the company has invested approximately RMB 4.1066 million (unaudited) in the research and development of this product.